Senile dementia of Alzheimer type

Cross AJ, Crow TJ, Johnson JA Monoamine metabolism in senile dementia of Alzheimer type. J Neurol Sci 60 383-393, 1983... 

Perry EK, Perry RH, Blessed G, et al Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 4 273-277,1978a... 

Mishima K, Tozawa T, Satoh K, MatsumotoY, HishikawaY, Okawa M (1999) Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer s type with disturbed sleep-waking. Biol Psychiatry 45 417-421... 

Iversen LL, Rossor MN, Reynolds GP, Hills R, Roth M, Mountjoy CQ, Foote SL, Morrison JH, Bloom FE (1983) Loss of pigmented dopamine-beta-hydroxylase positive cells from locus coeruleus in senile dementia of Alzheimer s type. Neurosci. Lett. 39 95-100. 

Wilcock GK, Esiri MM, Bowen DM, Hughes AO (1988) The differential involvement of subcortical nuclei in senile dementia of Alzheimer s type. J. Neurol. Neurosurg. Psychiatry 51 842-849. 

Soderberg M., Edlund C., Alafuzoff 1. et al. Lipid composition in different regions of the brain in Alzheimer s disease/senile dementia of Alzheimer s type. J. Neurochem. 1992,5 1646-1653. 

By 1989, about 2000 individuals in the Minamata area have been officially certified to have Minamata Disease and eligible for financial compensation. Histopathologi-cal changes in brain were clearly linked to organomercury insult in Minamata Disease victims and the distribution of lesions in the nervous system was characteristic, especially in the cerebral cortices and the cerebellum. Pathological studies of 112 Minamata Disease victims also showed elevated frequencies of sepsis and malignant neoplasms of the thyroid gland when compared to 112 sex-age matched pair control deaths between 1970 and 1983 from various causes (senile dementia of Alzheimer s type, Parkinson s disease of idiopathic type, amyotrophic lateral sclerosis) in western parts of Japan. 

McCaddon, A., Davies, G., Hudson, P., Tandy, S., and Cattell, H., 1998. Total serum homocysteine in senile dementia of Alzheimer s type. International Journal of Geriatric Psychiatry. 13 235-239. 

Soderberg M, Edlund C, Alafuzoff I, Kristensson K, Dallner G. lipid composition in different regions of the brain in Alzheimer s disease/senile dementia of Alzheimer s type. J Neurochem. 1992 59(5) 1646-1653. Svennerholm L, Gottfries CG. Membrane Upids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (t)fpe I) and demyelinationin late-onset form (t)fpe II). / Neurochem. 

Other nootropic agents in some stage of clinical development include nebracetam (9), nefinacetam (10), and BMY 21502 (11). Nebracetam, an aminomethyl pyrrolidinone derivative, is expected to be approved in Japan in 1994 (73). In clinical studies involving patients having cerebrovascular or senile dementia of the Alzheimer s type, clinical symptoms such as spontaneous or emotional expression were enhanced in up to 71% of cases. Long-term treatment using nebracetam in patients with cerebral infarction also afforded marked improvement in most cases with few side effects (74). A review of this compound has beenpubUshed (75). 

Manning CA, Ragozzino ME and Gold PE (1993). Glucose enhancement of memory in patients with senile dementia of the Alzheimer type. Neurobiology of Ageing, 14, 523-528. 

The first neurochemical evidence of a disturbed serotonin function in cognition came from the changes in serotonin and/or 5-hydroxyindoleacetic acid (5-HIAA) levels in a number of forebrain nuclei, the temporal and cingulate cortex, hippocampus, and other areas of the brain taken at autopsy from patients with senile dementia of the Alzheimer s type (Adolfsson et al. 1978 Arai et al. 1984 D. M. Bowen et al. 1979, 1983 A. J. Cross et al. 1983 Winblad et al. 1982). The depletions are regionally selective reductions in se-... 

Similar results were obtained from material taken from patients with senile dementia of the Alzheimer s type (Chan-Palay et al. 1992). A loss of tryptophan hydroxylase immunoreactive neurons in the raphe nuclei, which was most pronounced in the lateral division, was correlated with both age and cortical pathology. Furthermore, tyrosine hydroxylase reactive neurons were also found to be reduced in the locus coeruleus, even more so than the tryptophan hydroxylase reactive neurons. The same was also found for material taken from brains with Parkinson s disease. 

Chan-Palay V, Asan E Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson s disease with and without dementia and depression. J Comp Neurol 287 373-392, 1989... 

Chan-Palay V, Hochh M, Jentsch L, et al Raphe serotonin neurons in the human brain stem in normal controls and patients with senile dementia of the Alzheimer type and Parkinsons disease relationship to monoamine oxidase enzyme localization. Dementia 3 253-269, 1992... 

Chatelher G, Lacomblez L Tacrine (tetrahydroamino-acridine THA) and lecithin in senile dementia of the Alzheimer type a multicentre trial. BMJ 300 495-499, 1990... 

Drevets WC, Rubin EH Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry 25 39-48, 1989... 

Dysken MW, Mendels J, LeWitt P Milacemide a placebo-controlled study in senile dementia of the Alzheimer type. J Am Geriatr Soc 40 503-506, 1992 Dysken MW, Johnson SB, Holden L, et al Haloperidol concentrations in patients with Alzheimer s Disease. Am J Geriatr Psychiatry 2 124-133, 1994 Eagger SA, Levy R, Sahakian BJ Tacrine in Alzheimer s disease. Lancet 337 989-929, 1991... 

Prince DA, Wilder BJ Cortical mechanisms in cortical epileptogenic foci surrounded inhibition. Arch Neurol 16 194-202, 1967 Prinz PN, Vitahano PP, Vitiello MV, et al Sleep, EEC and mental function changes in senile dementia of the Alzheimer s type. Neurobiol Aging 3 361-370, 1982... 

Becker, R F., Giacobini, E. Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type clinical, pharmacological and therapeutic aspects. Drug Dev. Res. 12. 163-195, 1988. 

Wettstein, A., Spiegel, R. Clinical trials with the cholinergic drug RS 86 in Alzheimer s disease (AD) and senile dementia of the Alzheimer type (SDAT). Psychopharmacology 84, 572-573, 1984. 

Samorajski T, Vroulis GA, Smith RC. Piracetam plus lecithin trials in senile dementia of the Alzheimer type. Ann N Y Acad Sci 1985 444 478-81. 

A 92-year-old man with a history of senile dementia of the Alzheimer type, glaucoma, and constipation took indometacin 25 mg for pseudogout. After six doses he became very agitated and confused and was physically and verbally aggressive. Indometacin was withdrawn and he recovered over 10 days with the help of halo-peridol 0.5 mg/day (558). 

---